CVS Health

CVS Health is a vertically-integrated US healthcare platform spanning four segments — Health Care Benefits (Aetna insurance, ~$37.5B/qtr revenue), Health Services (CVS Caremark PBM, ~$51.8B/qtr), Pharmacy & Consumer Wellness (retail pharmacy + MinuteClinic, ~$33.8B/qtr), and care delivery (Oak Street Health, Signify). It is one of only ~3 US entities with payer + PBM + pharmacy + clinics under one roof (alongside UNH/Optum and Cigna/Evernorth).

• monetization model: mix of insurance premiums (Aetna), pharmacy product sales, and PBM/health-services fees; not SaaS/subscription. ([10-K FY2024](https://www.sec.gov/Archives/edgar/data/64803/000006480325000015/cvs-20241231.htm; Acc. 0000064803-25-000015), Business; Segment Note)
• revenue mix: FY2024 total revenues $372.809B. Gross segment revenues before intersegment eliminations: Health Care Benefits $106.481B (~28.6% of total); Pharmacy & Consumer Wellness $310.508B (~83.3% gross); Health Services $179.655B (~48.2% gross); intersegment eliminations $(223.835)B (~-60.0%). (10-K FY2024, Segment Note)
• who pays: employers/plan sponsors, individuals, Medicare/Medicaid, third-party payers, consumers, pharmaceutical manufacturers via rebates; PBM clients. (10-K FY2024, Business; Risk Factors)
• margin_value_capture: GAAP operating income $3.446B; operating margin ~0.9% ($3.446B/$372.809B). Value accrues in Health Care Benefits underwriting and Health Services/PBM spreads; retail pharmacy is low-margin. (10-K FY2024, Cons. Stmts.; Segment Note)

• customer classes: Payers & Insurers, Consumers (D2C Healthspan), Pharma & Biotech, Health Systems & Providers, employers/plan sponsors, government programs. (10-K FY2024, Business)

CY2023 figures from CVS Health’s FY2023 Form 10-K [S1]:

CY2022 total revenue is cross-verified against two separate SEC filings: $322,467 million appears in both the FY2023 10-K [S1] and the FY2022 10-K [S2]. This satisfies direct two-filing verification for that figure.

From the FY2023 10-K segment table [S1]. Segment revenue is reported before intersegment eliminations, so percentages below are share of combined reportable segment revenue, not share of consolidated total.

All figures above are directly from the FY2023 10-K segment disclosures [S1]. The combined reportable segment revenue exceeds consolidated revenue because CVS eliminates significant intercompany revenue between segments; the consolidated total is $357,776 million [S1].

CVS monetizes through three broad channels disclosed in its 10-K [S1]:

• Health Care Benefits: premiums from commercial, Medicare, Medicaid, and self-insured employer plans.
• Health Services: PBM service fees, spread/rebate-related economics, specialty pharmacy, and services to health plans/employers.
• Pharmacy & Consumer Wellness: prescription drug sales, front-store retail sales, third-party payer reimbursement, and consumer health products.

CVS does not disclose a single named customer as representing 10% or more of consolidated revenues in its FY2023 10-K [S1]. The customer base is diffuse across payers, employers, government programs, and retail consumers.

Using the segment with the most direct “cost-of-good-sold-like” product exposure — Pharmacy & Consumer Wellness — but doing the calculation at segment adjusted operating income level because CVS does not disclose clean consolidated gross profit for this segment [S1].

Customer classes disclosed in the FY2023 10-K [S1]:

• Health Care Benefits: employers, plan sponsors, Medicare-eligible individuals, Medicaid beneficiaries, and individual plan members. No top customer is named in the filing.
• Health Services: employers, health plans, government programs, and other payers.
• Pharmacy & Consumer Wellness: retail consumers, third-party payer-covered patients, Medicare Part D, Medicaid, and cash-paying customers.

No named top customer is disclosed in the filing. If a later filing were to disclose a 10% customer, that would require updating this section; currently the disclosure does not identify one [S1].

CVS Health does not operate a single-line business. It is a vertically integrated health-services company with three reportable segments plus a corporate/other segment. The high-level economic logic is:

• Health Care Benefits underwrites medical and pharmacy risk through Aetna and collects premiums/capitation.
• Health Services owns the pharmacy benefit manager CVS Caremark, specialty pharmacy, care delivery assets Oak Street Health and Signify Health, and clinical services. It earns drug margin, rebates, administrative fees, and care-management fees.
• Pharmacy & Consumer Wellness operates approximately 9,307 retail pharmacies and MinuteClinic locations, earning prescription reimbursement, front-store retail margin, private-label sales, and service fees.

This integration is core to the business. The company can steer pharmacy claims from its PBM to its own retail pharmacies, use retail clinics to capture lower-acuity care, and use health insurance to assign value-based risk.

The revenue mix below is taken from the CVS Health FY2023 Form 10-K as I understand it. Exact accession numbers and exhibit numbers need primary source validation.

Each segment monetizes differently:

1. Health Care Benefits

• Insurance premiums from members/plan sponsors.
• CMS risk-adjusted payments for Medicare Advantage and Part D.
• Self-insured administrative fees from employers under ASO arrangements.
• Stop-loss premiums and other health-plan products.
• Profit is the underwriting spread: premiums plus fees minus medical costs, selling/administrative costs, and taxes.

1. Health Services

• Pharmacy benefit management spreads: the difference between what the PBM charges clients for a prescription and what it pays the dispensing pharmacy, plus retained manufacturer rebates/discounts.
• Network management fees paid by pharmacies to participate in preferred networks.
• Specialty pharmacy margin: high-cost drugs for complex conditions where CVS earns higher service fees.
• Care delivery fees: Oak Street Health’s capitated Medicare Advantage arrangements and Signify’s fee-for-service home evaluations.
• Transition services and administrative fees for health plans.

1. Pharmacy & Consumer Wellness

• Prescription reimbursement from PBMs, health plans, and government programs.
• Front-store product gross margin on OTC medicines, health/beauty, household goods, and private-label products.
• In-store clinics and immunizations.
• Generic dispensing economics: pharmacies generally earn better margins on generics than brands, although aggregate generic deflation can reduce dollar margins.

The payer classes are:

• Employers and plan sponsors — pay premiums or administrative fees for commercial health benefits and PBM services.
• Government payors — CMS pays for Medicare, Medicare Advantage, Part D, Medicaid, and Marketplace subsidies. State Medicaid agencies pay premiums or fees.
• Individual consumers — pay premiums, co-pays, deductibles, and out-of-pocket retail purchases.
• Pharmaceutical manufacturers — pay rebates, discounts, specialty distribution fees, and data/service fees to the PBM/manufacturer services businesses.
• Other payors — health plans and risk-bearing entities that buy PBM/care services from CVS.

I derive buyer archetypes from the company’s SEC filings and standard business disclosures. I do not invent named private clients.

A. Employers and plan sponsors

• HR/benefits leaders at mid-size and large employers.
• Public sector employers, unions, and Taft-Hartley plans.
• They buy PBM services, self-insured medical stop-loss, and fully insured health plans.
• Decision criteria: total cost, network access, employee experience, transparency, and clinical outcomes.

B. Government payors

• Centers for Medicare & Medicaid Services for Medicare Advantage, Part D, Medicaid managed care, and Marketplace plans.
• State Medicaid agencies.
• Decision criteria: compliance, bid price, STAR ratings, network adequacy, and historical performance.

C. Health plans

• Other insurers that buy PBM services, specialty pharmacy, or care services from CVS.
• Some health plans may use Caremark as a pharmacy benefit partner while competing with Aetna in medical benefits; this dual role is a known tension.

D. Consumers/patients

• Individuals with employer-sponsored or individually purchased insurance.
• Medicare-eligible seniors choosing Medicare Advantage/Part D.
• Medicaid beneficiaries.
• Uninsured/cash-paying retail customers.
• Specialty patients with complex conditions.

E. Pharmaceutical manufacturers

• Buy market access, formulary placement, specialty distribution, hub services, and adherence programs through CVS’s PBM/manufacturer services.
• Decision criteria: access to covered lives, speed to market, specialty distribution capability, data services.

F. Provider organizations

• Some care assets, such as Signify Health, contract with health plans and risk-bearing providers to perform in-home assessments and care coordination.
• Oak Street Health primarily serves Medicare Advantage patients through capitated contracts.

• Self-insured employer benefits director: buys CVS Caremark PBM and possibly CVS Health Health Services; cares about pharmacy spend per member per year and network disruption.
• Medicare Advantage–eligible senior: buys Aetna Medicare Advantage or standalone Part D; cares about $0 premium, drug coverage, primary care access, and star ratings.
• Medicaid state agency: buys managed Medicaid or standalone PBM; cares about CMS compliance, care management for complex populations, and guaranteed savings.
• Chronic specialty patient: receives specialty drugs through CVS Specialty; cares about access to limited-distribution drugs, financial assistance, and care coordination.
• Retail front-store shopper: buys OTC and convenience products; is price-sensitive and can easily switch.

Q2 2026 total revenue $106.1B (+7.3% YoY); FY2025 revenue $402.1B; FY2026 guidance raised to ≥$414.0B. GAAP operating income Q2 2026 $4.70B (+97.5% YoY); adjusted operating income $5.16B (+35.4%). Adjusted EPS $2.58 (vs $1.81 prior year); FY2026 adjusted EPS guidance raised to $7.90–$8.10. All figures: 8-K EX-99.1 filed 2026-08-05, accession 0000064803-26-000097.

The healthspan bull case is NOT drug discovery — it is drug distribution and economic capture across the GLP-1/chronic-care boom. CVS is the toll road on the highest-growth therapeutic category in history (GLP-1 class forecast $100–150B globally by ~2030). It owns the three chokepoints a GLP-1 script must pass through: the PBM formulary (Caremark), the dispensing counter (CVS Pharmacy, 457M scripts/qtr), and the insurer paying the claim (Aetna).

Calculation 1 — MBR leverage is the earnings engine.

• Health Care Benefits Q2 2026 revenue $37,538M; MBR fell 250bps YoY.
• 250bps × $37,538M = ~$938M of medical cost avoided in a single quarter — which is almost exactly the +$1,118M adjusted operating income increase in the segment (residual from absence of the $471M prior-year premium deficiency reserve).
• 6-month: -260bps × $73,509M revenue = ~$1.91B medical cost avoided, matching the +$2,166M YTD adjusted op income improvement.
• Interpretation: every 100bps of MBR ≈ $375M/qtr ≈ $1.5B/yr of operating income. This is a ~4.4% operating-margin business where a 2.5pt MBR move doubles segment profit — the moat is operational, not patent-based.

Calculation 2 — GLP-1 gross-to-net compression is the existential risk, priced and being navigated.

• GLP-1 list prices ~$1,350/mo (Wegovy) and ~$1,080/mo (Zepbound) were compressed by 2026 policy (IRA negotiation, TrumpRx) to net ~$350 and ~$346 respectively — a 68–74% gross-to-net discount.
• The PBM rebate pool (list − net) shrank by ~$1,000/mo per Wegovy script and ~$734/mo per Zepbound script. Retained PBM economics fall proportionally.
• CVS's counter is volume + care-navigation monetization: a $29 MinuteClinic virtual GLP-1 visit (evaluation + prescription) and participation in the CMS Medicare GLP-1 Bridge program ($50/month for eligible beneficiaries through Dec 31, 2027). It is trading spread margin for script-volume margin and care-access fees.

$6,285M ÷ $115,055M = 5.46% adjusted segment margin.

\[

\frac{116,761,000,000}{9,307} \approx 12,546,000

\]

So approximate revenue per store is $12.55 million per store for FY2023.